These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 18395940)

  • 1. Neurovascular coupling in Alzheimer patients: effect of acetylcholine-esterase inhibitors.
    Rosengarten B; Paulsen S; Burr O; Kaps M
    Neurobiol Aging; 2009 Dec; 30(12):1918-23. PubMed ID: 18395940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
    Aguglia E; Onor ML; Saina M; Maso E
    Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurovascular coupling in Parkinson's disease patients: effects of dementia and acetylcholinesterase inhibitor treatment.
    Rosengarten B; Dannhardt V; Burr O; Pöhler M; Rosengarten S; Oechsner M; Reuter I
    J Alzheimers Dis; 2010; 22(2):415-21. PubMed ID: 20847429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
    Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
    Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting.
    Frankfort SV; Appels BA; De Boer A; Tulner LR; Van Campen JP; Koks CH; Beijnen JH
    Int J Clin Pract; 2006 Jun; 60(6):646-54. PubMed ID: 16805746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ApoE epsilon4 allele on visual evoked potentials and resultant flow coupling in patients with Alzheimer.
    Rosengarten B; Paulsen S; Burr O; Kaps M
    J Geriatr Psychiatry Neurol; 2010 Sep; 23(3):165-70. PubMed ID: 20430978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests.
    Borkowska A; Ziolkowska-Kochan M; Rybakowski JK
    Hum Psychopharmacol; 2005 Aug; 20(6):409-14. PubMed ID: 15991260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].
    Wobrock T; Retz-Junginger P; Retz W; Supprian T; Rösler M
    Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term rivastigmine treatment in a routine clinical setting.
    Minthon L; Wallin AK; Eriksson S; Wattmo C; Andreasen N
    Acta Neurol Scand; 2009 Mar; 119(3):180-5. PubMed ID: 18759798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
    Gauthier S; Juby A; Morelli L; Rehel B; Schecter R;
    Curr Med Res Opin; 2006 Nov; 22(11):2251-65. PubMed ID: 17076986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
    Erkinjuntti T; Skoog I; Lane R; Andrews C
    Int J Clin Pract; 2003 Nov; 57(9):756-60. PubMed ID: 14686563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategic subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patients.
    Behl P; Bocti C; Swartz RH; Gao F; Sahlas DJ; Lanctot KL; Streiner DL; Black SE
    Arch Neurol; 2007 Feb; 64(2):266-72. PubMed ID: 17296844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
    Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
    Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rivastigmine in a case of autopsy proved frontotemporal dementia (Pick's disease)].
    Calatayud-Noguera T; Astudillo-González A; Alvarez-Carriles JC; Temprano-Fernández T; Cortés-Velarde M; Oliva-Nacarino P
    Rev Neurol; 2009 Jun 1-15; 48(11):582-4. PubMed ID: 19472156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
    Small GW; Kaufer D; Mendiondo MS; Quarg P; Spiegel R
    Int J Clin Pract; 2005 Apr; 59(4):473-7. PubMed ID: 15853867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertension, white matter change and response to cholinesterase inhibitors in Alzheimer's disease.
    Connelly PJ; Prentice NP; Fowler KG
    Int J Geriatr Psychiatry; 2005 Jul; 20(7):623-8. PubMed ID: 16021654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of rivastigmine in routine clinical practice.
    Frankfort SV; Appels BA; de Boer A; Tulner LR; van Campen JP; Koks CH; Beijnen JH
    Int J Geriatr Psychiatry; 2005 Dec; 20(12):1167-71. PubMed ID: 16315150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
    Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
    Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.